Literature DB >> 11988491

Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene.

J Silence1, D Collen, H R Lijnen.   

Abstract

Development and progression of atherosclerotic lesions and aneurysm formation were investigated in mice with single or combined deficiency of apolipoprotein E (ApoE) and tissue inhibitor of metalloproteinase-1 (TIMP-1) kept on a cholesterol-rich diet for 30 weeks. Atherosclerotic lesions throughout the thoracic aorta were significantly (P<0.001) larger in mice wild-type for TIMP-1 (ApoE-/-:TIMP-1+/+) than in mice deficient in TIMP-1 (ApoE-/-:TIMP-1-/-). Aneurysms in the thoracic and abdominal aortas were less frequent in ApoE-/-:TIMP-1+/+ mice than in ApoE-/-:TIMP-1-/- mice (11+/-3.0 versus 23+/-5.1 aneurysms per 100 sections analyzed, mean+/-SD, P<0.001). Immunocytochemistry revealed enhanced accumulation of Oil red O-stained lipids, colocalizing with macrophages in atherosclerotic lesions of ApoE-/-:TIMP-1-/- mice (P<0.05). In situ zymography using a casein substrate showed enhanced lysis in plaques of ApoE-/-:TIMP-1-/- mice as compared with ApoE-/-:TIMP-1+/+ mice (P<0.01). MMP activity was most pronounced at sites where degradation of the elastic lamina occurred. These data suggest that enhanced MMP activity, as a result of TIMP-1 deficiency, contributes to a reduction of atherosclerotic plaque size but promotes aneurysm formation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11988491     DOI: 10.1161/01.res.0000016501.56641.83

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  34 in total

Review 1.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

Review 2.  Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Authors:  Takayuki Shiomi; Vincent Lemaître; Jeanine D'Armiento; Yasunori Okada
Journal:  Pathol Int       Date:  2010-07       Impact factor: 2.534

Review 3.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 4.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

5.  Matrix metalloproteinases and cardiovascular diseases.

Authors:  A Papazafiropoulou; N Tentolouris
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

Review 6.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 7.  Molecular pathogenesis of genetic and sporadic aortic aneurysms and dissections.

Authors:  Ying H Shen; Scott A LeMaire
Journal:  Curr Probl Surg       Date:  2017-02-03       Impact factor: 1.909

Review 8.  Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms.

Authors:  Yanwen Qin; Xu Cao; Yaoguo Yang; Guo-Ping Shi
Journal:  Future Cardiol       Date:  2013-01

9.  Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes.

Authors:  Andrew C Newby; Sarah J George; Yasmin Ismail; Jason L Johnson; Graciela B Sala-Newby; Anita C Thomas
Journal:  Thromb Haemost       Date:  2009-06       Impact factor: 5.249

10.  Ascending thoracic aortic aneurysms protect against myocardial infarctions.

Authors:  Katherine Chau; John A Elefteriades
Journal:  Int J Angiol       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.